1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Big Pharma Leads Development Of Novel Antibody-Drug Conjugates

 
• By Elizabeth Cairns

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.    

Antibody Drug Conjugate

The knockback of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd.’s patritumab deruxtecan (DXd) this week, and the late-stage lung cancer misfire of AstraZeneca PLC and Daiichi Sankyo’s datopotamab DXd, shows that developing antibody-drug conjugates (ADCs) is no easy task.

Key Takeaways
  • 11 not-yet-approved antibody-drug conjugates are in Phase III trials.
  • Merck & Co and AstraZeneca have the most advanced compounds, both of which are partnered with Daiichi Sankyo, but both have run into trouble

But many companies are trying, lured by the extraordinary success of approved products such as AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab DXd)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.